Ian J. Kulac

Oct 9, 2024 | jacc.org | Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac |Akshay S. Desai

AbstractBackgroundFinerenone has kidney protective effects in patients with chronic kidney disease (CKD) with type 2 diabetes, but effects on kidney outcomes in patients with heart failure (HF) with and without diabetes and/or CKD are not known. ObjectivesExamine the effects of finerenone on kidney outcomes in FINEARTS-HF, a randomized trial of finerenone vs. placebo among patients with HF with mildly reduced or preserved ejection fraction.

Sep 29, 2024 | jacc.org | Akshay S. Desai |Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac

IntroductionHospitalization for management of worsening HF symptoms has long been recognized as a sentinel event with important prognostic implications.

Mar 15, 2024 | onlinelibrary.wiley.com | Alexander Peikert |Muthiah Vaduganathan |Brian Claggett |Ian J. Kulac

Introduction Coronary artery disease is highly prevalent in patients with heart failure (HF).1, 2 Indeed, in many patients, myocardial ischaemia may represent a central driver of worsening HF and disease progression.

Jul 4, 2023 | onlinelibrary.wiley.com | Peder Myhre |Yuxi Liu |Ian J. Kulac |Brian Claggett

ABSTRACT Background Adrenomedullin is a vasodilatory peptide with a role in microcirculatory and endothelial homeostasis. Adrenomedullin is a substrate for neprilysin and may therefore play a role in beneficial effects of sacubitril/valsartan (Sac/Val) treatment.